| TEAE . | SAD . | MAD . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Placebo (n = 10) . | 0.1 mg (n = 6) . | 0.4 mg (n = 6) . | 0.8 mg (n = 6) . | 1.2 mg (n = 5) . | 1.5 mg (n = 6) . | Placebo (n = 6) . | 1.2 mg q.d. (n = 6) . | 0.8 mg b.i.d. (n = 6) . | 1.0 mg b.i.d. (n = 6) . | |
| Injection site reactions | 5 | 3 | 6 | 6 | 5 | 6 | 5 | 6 | 6 | 6 |
| Dizziness | 1 | 1 | — | 2 | 1 | 4 | 1 | 4 | 2 | 3 |
| (Orthostatic) hypotension | — | 2 | 1 | 2 | — | 3 | 4 | 6 | 5 | 5 |
| Abdominal complaints | — | — | — | 1 | — | — | 1 | 2 | 5 | 5 |
| Nausea | — | — | — | 1 | — | 2 | 1 | 3 | 4 | 4 |
| Vomiting | — | — | — | — | — | — | — | — | 1 | 1 |
| TEAE . | SAD . | MAD . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Placebo (n = 10) . | 0.1 mg (n = 6) . | 0.4 mg (n = 6) . | 0.8 mg (n = 6) . | 1.2 mg (n = 5) . | 1.5 mg (n = 6) . | Placebo (n = 6) . | 1.2 mg q.d. (n = 6) . | 0.8 mg b.i.d. (n = 6) . | 1.0 mg b.i.d. (n = 6) . | |
| Injection site reactions | 5 | 3 | 6 | 6 | 5 | 6 | 5 | 6 | 6 | 6 |
| Dizziness | 1 | 1 | — | 2 | 1 | 4 | 1 | 4 | 2 | 3 |
| (Orthostatic) hypotension | — | 2 | 1 | 2 | — | 3 | 4 | 6 | 5 | 5 |
| Abdominal complaints | — | — | — | 1 | — | — | 1 | 2 | 5 | 5 |
| Nausea | — | — | — | 1 | — | 2 | 1 | 3 | 4 | 4 |
| Vomiting | — | — | — | — | — | — | — | — | 1 | 1 |
Presented are the numbers of subjects per treatment who experienced a specific TEAE.
Abbreviations: b.i.d., twice-daily dosing; q.d., once-daily dosing.
| TEAE . | SAD . | MAD . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Placebo (n = 10) . | 0.1 mg (n = 6) . | 0.4 mg (n = 6) . | 0.8 mg (n = 6) . | 1.2 mg (n = 5) . | 1.5 mg (n = 6) . | Placebo (n = 6) . | 1.2 mg q.d. (n = 6) . | 0.8 mg b.i.d. (n = 6) . | 1.0 mg b.i.d. (n = 6) . | |
| Injection site reactions | 5 | 3 | 6 | 6 | 5 | 6 | 5 | 6 | 6 | 6 |
| Dizziness | 1 | 1 | — | 2 | 1 | 4 | 1 | 4 | 2 | 3 |
| (Orthostatic) hypotension | — | 2 | 1 | 2 | — | 3 | 4 | 6 | 5 | 5 |
| Abdominal complaints | — | — | — | 1 | — | — | 1 | 2 | 5 | 5 |
| Nausea | — | — | — | 1 | — | 2 | 1 | 3 | 4 | 4 |
| Vomiting | — | — | — | — | — | — | — | — | 1 | 1 |
| TEAE . | SAD . | MAD . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Placebo (n = 10) . | 0.1 mg (n = 6) . | 0.4 mg (n = 6) . | 0.8 mg (n = 6) . | 1.2 mg (n = 5) . | 1.5 mg (n = 6) . | Placebo (n = 6) . | 1.2 mg q.d. (n = 6) . | 0.8 mg b.i.d. (n = 6) . | 1.0 mg b.i.d. (n = 6) . | |
| Injection site reactions | 5 | 3 | 6 | 6 | 5 | 6 | 5 | 6 | 6 | 6 |
| Dizziness | 1 | 1 | — | 2 | 1 | 4 | 1 | 4 | 2 | 3 |
| (Orthostatic) hypotension | — | 2 | 1 | 2 | — | 3 | 4 | 6 | 5 | 5 |
| Abdominal complaints | — | — | — | 1 | — | — | 1 | 2 | 5 | 5 |
| Nausea | — | — | — | 1 | — | 2 | 1 | 3 | 4 | 4 |
| Vomiting | — | — | — | — | — | — | — | — | 1 | 1 |
Presented are the numbers of subjects per treatment who experienced a specific TEAE.
Abbreviations: b.i.d., twice-daily dosing; q.d., once-daily dosing.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
